%0 Journal Article 
%A Pereyra-Rodríguez, José Juan
%A Dominguez-Cruz, Javier
%A Ruiz-Villaverde, Ricardo
%A Silvestre-Salvador, Juan Fancisco
%A Galán Gutiérrez, Manuel
%A Curto-Barredo, Laia
%A Figueras-Nart, Ignasi
%A Serra-Baldrich, Esther
%A Armario Hita, José Carlos
%T Drug survival of systemic and biological treatments for moderate-to-severe atopic dermatitis in adults: a multicentre retrospective observational study
%D 2021
%@ 1365-2133
%U http://hdl.handle.net/10498/39523
%X This study provides a comparative survival analysis among most treatments available for moderate-to-severe AD. Regarding systemic drug survival, our findings are in reasonable
agreement with previous studies. Considering survival analysis as a reflection of the performance of a drug in daily practice, the results for dupilumab in our study demonstrate a clear superiority in terms of persistence compared with systemic
therapy. The dropout rate for the dupilumab group was only 6% in 20 months, whereas it was above 65% for all the other drugs under study. A limitation of this study is
the retrospective design, which is dependent on the quality of the medical records.
%K atopic dermatitis
%~ Universidad de Cádiz